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Introduction
One of the most encouraging trends in oncology over the past 
25 years has been the improvement in patient survival rates. 
While this phenomenon can be attributed to the develop-
ment and clinical application of a number of novel therapeu-
tic agents, the overall impact of supportive care measures in 
reducing cancer-related morbidity, and possibly even mortality, 
should not be underestimated.1 The latter belief is supported, 
in part, by a better understanding of the complex molecular 
and biochemical pathways that regulate treatment-associated 
adverse effects. For example, recognition of the 5-HT3 and 
NK1 receptor pathways in nausea and vomiting as well as 
identification of key proteins that regulate granulopoiesis led 
to the development of agents, which continues to have a sub-
stantial impact on clinical oncology.2 However, highlighting 
some of these notable achievements also exposes one glaring 
deficiency – the inability to prevent, or even attenuate, cancer 
treatment-induced neuropathy.
The relevance of this toxicity is further accentuated by 
the observation that, in some instances, effective therapy must 
be aborted, not because of drug resistance or disease progres-
sion, but rather the negative impact of neurotoxicity on the 
patient’s quality of life.3 The numerous mechanisms purport-
edly involved in the genesis of the neuronal toxicity are also 
important. The list includes, but may not be limited to, the 
toxic effects on dorsal root ganglia and mitochondria, altered 
neuronal blood supply, interference of axonal ion channels, 
and production of reactive oxygen species and inflammatory 
cytoki nes.4–8 Notwithstanding reports that neuroprotection 
could be achieved in the laboratory by targeting or abolishing a 
number of neurodegenerative events or modulating the balance 
of critical proteins, clinical trials have not produced conclu-
sive evidence to validate any preventive strategy. Indeed, the 
ongoing uncertainty regarding the precise pathophysiology of 
cancer treatment-induced neuropathy has impeded the deve-
lopment of at least one clinically effective protective measure.
Despite the likelihood that different mechanisms exist 
for different classes of anticancer agents, a unifying concept 
is proposed in linking treatment-induced neurotoxicity with 
disruption of microtubule function. As such, this article was 
sequenced to provide the reader with: (1) a detailed primer of 
the physiology and dynamics of the microtubule, (2) an abbre-
viated primer of the beneficial (antitumor) and detrimental 
(neurotoxic) effects associated with inhibition of this complex 
polymer, and (3) a scientific rationale for a proof-of-concept 
clinical study.
As such, numerous publications, many old but of endur-
ing scientific merit, as well as other, more recently, published 
data were retrieved and extensively evaluated. While portions 
of the published literature were used to support the accuracy 
of the textual content, unresolved issues provided the oppor-
tunity for reasoned author opinions.
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Microtubule-organizing center
The centrosome is an intracellular entity, unique in that the 
organelle is not defined by a distinct membranous bound-
ary. Incorporated within the centrosome are two centrioles, 
unusual because nine triplet microtubule units form two struc-
turally symmetrical cylinders (Fig. 1). The centrioles, linked by 
fiber-like appendages and surrounded by pericentriolar mate-
rial, are comprised most notably of proteinaceous substances. 
However, the proteins are not of centrosomal origin exclusively 
but derive also from a labile pool in the cell cytoplasm. Access 
to this bicompartmentalized source of protein is facilitated by 
the lack of a clear demarcation between the centrosome and 
cytoplasm. Of the numerous proteins, the gamma (γ)-tubulin 
ring complex is among the most well-described components 
of the pericentriolar material. The importance of this protein 
is discussed later.
One of the most important activities that occur within 
the centrosome is nucleation and organization of the micro-
tubules. This centrosomal activity is a manifestation of both the 
pericentriolar content (which contains the requisite materials) 
and the centriole (which functions as the assembly platform for 
microtubule formation). The requisite structural elements of 
the microtubule are heterodimers of α- and β-tubulin (Fig. 2). 
Interestingly, while the two protein subunits exhibit less than 
50% amino acid homology, three-dimensional diffraction 
studies describe crystal structures that are strikingly similar 
with regard to their electron density.9 Formation of the tubulin 
heterodimers is an equally delicate process that requires addi-
tional proteins (ie, chaperones and other cofactors) that assist 
and provide conformational integrity related to dimer folding 
and unfolding, dimer interface, and polymerization.10,11 Proto-
filaments are formed by a unique sequence of events involv-
ing heterodimer elongation. Because lengthening occurs with 
polar opposite α-tubulin linked to β-tubulin, the developing 
asymmetrical construct engenders the exposed ends that are 
negative and positive, respectively. In addition, the redundancy 
of the heterodimeric structure is superficially, though errone-
ously, simplistic. Not overt is that only guanosine triphosphate 
bound to β-tubulin is hydrolyzed, despite the presence, and 
binding, of the purine nucleoside to both tubulin subunits. The 
“Daughter” centriole
“Mother” centriole
Microtubules
Fiber links centrioles 
figure 1. the centrosome. Components include two centrioles of which the more mature is designated mother. Cylindrical in nature, the centriole actually 
consists of nine triplet microtubular structures surrounded by pericentriolar material. the centrosome is responsible for nucleation of microtubules.
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subtle implication of this finding relates to polymer formation, 
which is believed to occur at the hydrolytic end.
The terminus where α-tubulin is exposed is relatively qui-
escent, a diskinetic state that is believed to be a consequence 
of firm inter-protofilament bonding.12 The practicality of this 
utilitarian conformation is supported by electron density map-
ping, which shows variable changes in microtubule length.13 
While the stochastic shifts between lengthening and shorten-
ing, the cardinal feature known as dynamic instability, occur 
primarily at the positive end, a reactive transitional state has 
also been observed. The presence of this intermediary phase 
appears to debunk the maxim that random shifting occurs 
exclusively at the β-tubulin end.14 Indeed, additional evidence 
demonstrated that severance of the β-tubulin end resulted, 
as expected, in rapid microtubule shrinkage (catastrophe) in 
the same vicinity. Surprisingly, restoration of growth (rescue) 
began shortly after ionizing radiation-induced injury to the 
α-tubulin end.
efficacy of conventional Antimicrotubule Agents
The tenet that inhibition of microtubule function would have 
important ramifications in oncology is strongly supported 
by different classes of antimicrotubule agents available for 
clinical use. Despite chemical and structural differences, 
the primary mechanism of their antitumor effect is believed 
to be mediated by either stabilizing or destabilizing micro-
tubule function.
Microtubule-stabilizing agents. Laboratory investi-
gation indicates that the taxanes mediate their antitumor 
activity primarily by blocking microtubule disassembly, thus 
kinetically stabilizing the polymer. What can be perceived 
as a rather soft effect is deceiving because crucial cell activi-
ties (and cell survival) depend on the unsullied dynamics 
and function of the microtubule. Seemingly consistent 
with this mellow disturbance is the finding that the mass 
spectrum of the microtubule is unaltered. Important also, 
the stabilizing agents inhibit tumor growth and survival 
by sequencing two critical events. Initially, drug binding 
to β-tubulin interrupts metaphase to anaphase transition-
ing, thereby interfering with the spindle pole resulting in 
mitotic arrest. Subsequently, impairment of spindle appa-
ratus activates (by uncertain mechanisms) multiple pro-
gramed cell death pathways including the caspases and Bcl-2 
family proteins.15–17
The taxanes purportedly bind to a taxoid site, which 
resides behind the M-loop on the luminal surface of β-tubulin 
(Fig. 3).9–12 Even though this specific locus was believed to 
be the primary binding site, subsequent studies suggested 
that taxane binding consisted of a two-site mechanism. Com-
putational molecular modeling with nuclear magnetic reso-
nance showed that binding initially involved an external pore 
type-1 site followed by sequestration onto the luminal taxoid 
site.18 Despite these findings, the dual-site mechanism still 
remains a hypothesis.
Nascent binding notwithstanding the taxane–microtubule 
interaction is a very complex phenomenon. Previously, the 
binding interface of these agents was believed to involve the 
M-loop and the H1-S2 loop of adjacent β-tubulin monomers, 
thus increasing the lateral interactions between protofila-
ments.12 Other investigators localized taxane binding to a site 
central to helices H1, H6, H7, and the B7-H9 on the M-loop.19 
However, in later studies, it was observed that displacement 
of the M-loop away from H6 in the β-monomer allosteri-
cally facilitated drug interaction with the H1-S2 loop.20 More 
recently, two studies also showed that the initial M-loop inter-
action promoted the curved-to-straight conformational change 
that occurs with tubulin incorporation into microtubules.21,22 
Nonetheless, while the binding docket for the taxanes resides 
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figure 2. Basic structure of the microtubule. (1 and 2) heterodimeric folding of α- and β-tubulin occur in the presence of molecular chaperones.  
(3) MaPs facilitate tubulin dimer elongation. (4) γ-tubulin (depicted by the hook-like appendage provides directional guidance for microtubule 
polymerization. alternating rows of α (−) and β (+) heterodimers result in a structure with defined polarity. (5) Growth of the microtubule occurs 
preferentially at the plus end. Random transgressions between lengthening and shortening distinguish a utilitarian behavior known as dynamic instability.
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on β-tubulin, precise mapping of the interactive site is still not 
fully agreed upon.
Microtubule-destabilizing agents. Drugs such as 
vincristine and vinblastine exhibit high-affinity binding 
to a different, though not necessarily uniquely named, site 
known as the “vinca domain,” which has been localized to 
β-tubulin.23 Drug-tubulin or drug-polymer binding dis-
rupts polymerization or induces structural depolymeriza-
tion, resulting in functional impairment of microtubule 
dynamics. Notably, the vinca alkaloids can have a negative 
effect on either process depending on drug concentration. 
For example, it has been shown that dynamic instability of 
cells in mediums containing low (ie, nanomolar) concentra-
tions of vinblastine was effectively disrupted by increasing 
the duration of the resting or pause interval; at 3-log higher 
drug concentrations, microtubules depolymerized.24 Of 
note also, the vinca alkaloids appear to have concentration-
dependent effects on polymer mass. At high concentrations, 
these agents decrease microtubule mass by inhibiting poly-
merization; at low concentrations, the vinca alkaloids inter-
fere with microtubule dynamics without appreciably affecting 
the polymer size.25 Propagation of microtubule chaos results 
in mitotic arrest between the metaphase and anaphase 
transition points.
Neurotoxicity Associated with conventional 
Antimicrotubule Agents
Despite what is arguably their target, the microtubule inhibi-
tors are not considered to be true targeting agents as is cur-
rently defined. As such, cell damage associated with these 
drugs is not restricted to the tumor but includes cells of many 
other (normal) tissues. One major aspect of bystander damage 
common to all agents that alter microtubule function involves 
neuronal tissue. While the severity of neuropathy usually 
varies with duration of therapy, neurotoxicity is the most fre-
quent treatment-limiting adverse effect of these agents. Even 
though it remains unclear why the peripheral nervous system 
is at particular risk, a number of alleged biological factors 
have been proposed. Because of the significant clinical conse-
quences, a critical analysis of existing data was performed to 
explain the underlying mechanisms of this tactile toxicity.
The neuronal framework is structurally composed of 
microtubules, neurofilaments, and microfilaments. Each of 
these separate, yet interactive, polymeric elements have very 
unique properties. Microtubules have a performance reper-
toire that includes a functional architectural role as well as 
serving as a cellular causeway for trafficking proteins and 
other components. These functions can be further elaborated 
upon. Although α- and β-tubulin monomers are synthesized 
in the cell body of the neuron, polymer formation takes place 
in the distal region of growing axons.26 The restrictive sites of 
these two processes highlight what appears to be an orderly 
transport of proteins, including tubulin and other micro-
tubule-associated proteins (MAPs), which are essential for the 
formation of the platform to support construction of the axonal 
cytoskeleton.27 In essence, the integrity of the nervous system, 
which relies on the directional transport of neurotransmitter 
from perikaryon to synaptic cleft, is largely dependent on a 
functional microtubule network.
One of the most intriguing (and perplexing) aspects of 
the axonal cytoskeleton relates to the marked difference in the 
regenerative ability of axons following injury between neurons 
of the central and peripheral nervous systems.28 One plau-
sible explanation for the difference was provided by investi-
gators studying traumatically injured axons.29 In their report, 
Conde et al discovered two distinct phenomena occurring 
at the damaged site. Subsequent to injury, bulbous swelling 
followed by internal retraction (hence the descriptive terms 
retraction bulbs) was observed in the axons of central origin. 
On the other hand, equally conspicuous inclusion bodies pro-
truded from the injured peripheral axons. Because of their 
restorative effect on axonal elongation, these reactive struc-
tures were labeled growth cones.30 What may have also con-
tributed to axonal repair were increased concentrations of 
microtubules. Arguably, the appearance of the microtubules 
at the damaged site could be perceived as being merely coin-
cidental. Alternatively, it is conceivable that the large assem-
blage and functional repertoire of the microtubules at the 
sites of axonal regrowth is consistent with the fundamental 
α-tubulin
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figure 3. One-dimensional representation of tubulin heterodimer with 
taxane-binding site on β-tubulin. even though the α and β subunits 
share high-sequence homology and common topology, taxane binding is 
believed to be localized to the center of helices h1-s2 loop, h6, and the 
B7-h9 of the M-loop.
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(and indispensable) role of the polymer in reversing growth 
cone stalling and re-establishing neuronal function.31
These data provide a credible explanation for neurotoxicity 
associated with microtubule dysfunction. As such, disruption 
of dynamic instability interferes not only with the cytoskeletal 
structure and network but also with the axonal transport and 
directional conduction of electrical impulses away from the 
cell body. In addition, the morbid (and usually reversible) and 
mortal (and almost always fatal) consequences associated with 
peripheral and, sometimes negligent, central administration 
of vincristine could be explained by the appearance of growth 
cones and retraction bulbs, respectively.32,33
One other important issue that needs to be addressed 
relates to the relatively selective injury to the peripheral ner-
vous system. The simplest explanation relates to the likelihood 
that most of the anticancer agents, including the micro-
tubule inhibitors, do not (or have negligible ability to) cross 
the blood–brain barrier.34 However, a more erudite precis’ 
on the topic revolves around the structural integrity of the 
microtubule after drug-related or trauma-induced injury that 
determines whether axons survive or die. Based on a several 
ingenious in vitro and in vivo studies, researchers observed 
that growth cones from injured peripheral axons exposed to 
increasing concentrations of a vinca analog underwent trans-
formation to bulb-like appendages, much like retraction 
bulbs found on the damaged axons of central nervous system 
origin.35 Notably, the transformed growth cones contained 
conspicuously disorganized (and dysfunctional) microtubules, 
features identical to the polymeric structures found in the 
central neuronal retraction bulbs. Likewise, the transformed 
cones were also devoid of regenerative ability. It is emphasized 
that the observed transformation was dependent on drug con-
centration. At high concentrations, growth cones underwent 
transformation in half of all the neurons compared with the 
neurons exposed to the control (drug-free) medium. This find-
ing could explain the recovery of peripheral neurotoxic reac-
tions associated with vinca alkaloid therapy.
With a reasonable amount of certainty, the observation 
that microtubule destabilization generated retraction bulbs 
would translate to the intriguing possibility that stabilization 
of the intact polymer should inhibit bulb formation. An inge-
nious study conducted to test this hypothesis involved con-
ditioning of CNS neurons in taxane-containing or control 
(saline) mediums.35 The laboratory results revealed strik-
ing differences. First, even though bulb-like appendices 
developed on damaged axons bathed in both mediums, the 
taxane-conditioned cells exhibited significantly fewer bulbous 
elements. Second, the retraction bulbs of the taxane-treated 
axons were unusually small in size compared with control. 
And third, the orientation and arrangement of axonal micro-
tubules in the smaller protuberant bodies were nearly identical 
to microtubules found in growth cones. These provocative data 
strongly suggest that microtubule stabilization hinders gene-
ration of retraction bulbs and either impedes axonal shortening 
or promotes axonal regrowth. These findings are even more 
remarkable when compared with studies using neurons from 
the peripheral nervous system, which showed no difference in 
axonal features regardless of the conditioning media. Whereas 
the collective findings infer that microtubule-stabilizing 
agents may be less toxic than destabilizing agents, these data 
also appear to provide insight of the molecular mechanisms 
underlying the development (and reversal) of drug-induced 
neurotoxicity. At the same time, it is important to stress the 
role of other components, including MAPs,36 nerve growth 
factor,37 intermediate filaments,38 as well as other proteins, 
such as actin microfilaments and plectin.39
Incidental Microtubule-damaging Agents
Although frequently associated with drugs that stabilize or 
destabilize the microtubule, significant neurotoxicity also 
develops during treatment with bortezomib and oxalipla-
tin. Not considered traditional antimicrotubule agents, these 
two drugs were included in this article because their surrep-
titious effects on the microtubule strengthen the belief that 
the tubulin complex may be the crux of cancer treatment- 
associated neurotoxicity.
Proteasome inhibitors. Bortezomib, a proteasome inhibi-
tor, represents an anomaly in oncology.40 Proteasomes are 
cytoplasmic and nuclear constituents of all eukaryotic cells. In 
conjunction with ubiquitin, the proteasome-ubiquitin pathway 
is responsible for the constitutive degradation of the majority 
of cellular proteins. The apparent aberration stems from the 
finding that targeted inhibition of the 26S proteasome, an 
essential component of cell metabolism, retards tumor pro-
gression by interfering with the orderly degradation of nor-
mal, key regulatory molecules. In essence, this pathway plays a 
pivotal role in regulating the balance between de novo protein 
synthesis and proteolysis.
Indeed, the link between microtubule and proteasome is 
strengthened by laboratory studies demonstrating localization 
of major elements of the proteasome–ubiquitin pathway to the 
centrosome in cells during interphase.41 And perhaps not sur-
prising was the observation that inhibition of the proteasome 
impinged on spindle dynamics, resulting in the fragmenta-
tion of the spindle apparatus.42 These intriguing findings led 
to further studies, one of which is most galvanizing. While 
it was known that various proteins (of which γ-tubulin is the 
best characterized) were ensconced within the pericentriolar 
material surrounding the centrioles,43 French investigators 
discovered that cells treated with proteasome inhibitors accu-
mulated large amounts of centrosomal proteins, including an 
insoluble form of γ-tubulin with a higher molecular weight.44 
Because microtubule nucleation is the event that initiates de 
novo polymerization of α-β tubulin dimers, an important 
question was to determine whether the accumulated pro-
teins could alter the capacity of the centrosome to nucleate 
microtubules. The researchers found that not only the protea-
some inhibitor, PS-341 (bortezomib), impaired microtubule 
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nucleation but the drug-treated cells also lacked a discernable 
microtubule-organizing center. Notably, allowing the cells 
to recover following drug removal resulted in the normaliza-
tion of both processes. Still, a couple of uncertainties exist. 
One relates to the functionality of insoluble γ-tubulin; and 
two, the precise mechanism underlying the accumulation of 
the centrosome proteins following proteasomal inhibition. 
Perhaps the most plausible explanation for the latter is failure 
of the proteasome to degrade poly-ubiquitylated proteins. 
While the importance of proper assembly and the number 
of centrosomes have been correlated with genetic instability 
and human cancer, it is conceivable that deregulation of 
microtubule organization could also be associated with drug- 
related neurotoxicity.
In addition to the proteasome inhibitors, the platinum 
compounds have had a major impact on the treatment of vari-
ous malignancies. Of the latter agents, oxaliplatin has emerged 
as one of the most important new cytotoxic drugs. Classified 
as an alkylating agent,45 this platinum analog contains a steri-
cally bulky ligand (1,2-diaminocyclohexane [DACH]) and a 
labile oxalate ligand, which distinguish this compound from 
cisplatin or carboplatin.46 Formation of site-specific DNA-
protein-oxaliplatin as well as inter-DNA-platinum crosslinks 
is believed to be the basis for inhibiting DNA transcription 
and replication. Interestingly, although fewer in number (com-
pared with cisplatin), the formed crosslinks are reported to be 
more potent, a finding possibly related to the DACH ligand.
Platinum agents. Oxaliplatin, a third-generation plati-
num agent, is considered one of the two most important new 
drugs used in the treatment of colorectal cancer. Despite the 
clinical impact and attendant enthusiasm for this agent, the 
applicability of oxaliplatin is limited, in large part, by sensory 
neuropathy. Importantly, neurotoxicity, not tumor progres-
sion, is the most frequent reason that forces patients to forego 
further therapy with this agent. Because the approved use of 
oxaliplatin has, for the first time in over 50 years, improved 
overall survival in patients with colorectal cancer, effective 
prophylaxis against this toxicity should still be considered a 
priority for innovative prevention research.
The biochemical mechanism of the neurotoxic reaction 
was initially believed to involve voltage-gated sodium channels 
through chelation of calcium by a metabolite of oxaliplatin.47 
The apparent, though small, benefit of calcium/magnesium 
infusions was consistent with the notion that altered calcium 
homeostasis may have a role in inducing neurotoxicity.48 How-
ever, results of a definitive clinical trial showed that calcium 
(and magnesium) infusions have no proven benefit against 
oxaliplatin-induced neurotoxicity.49
More recently, studies in animal models strongly suggest 
the role of transport mechanisms in platinum-induced neuro-
toxicity. Ciarimboli et al reported that accumulation of drug 
in, and damage to, neuronal cells was linked to organic cation 
transporter 2 (OCT2), a protein expressed in the neurons 
of the dorsal root ganglia.50,51 Interestingly, overexpression 
of OCT2 resulted in a significant (up to 35-fold) increase 
in neuronal uptake of oxaliplatin, while OCT2 gene knock-
out protected against the development of peripheral neuro-
toxicity.52 However, a potential obstacle related to targeting 
OCT2 for preventive therapy is that the protein belongs to a 
major facilitator superfamily of transporters, which includes 
OCT1–3 (electrogenic cation transporters), OCTN1–3 (elec-
troneutral cation transporters), and OAT1–5 (organic anion 
transporters). Indeed, repression of the transporter’s direct 
impact of drug uptake into neuronal cells could, simultane-
ously, antagonize the antitumor effect since many of these 
transporters, including OCT2, are expressed in the tissues of 
the gastrointestinal tract.53
Integrated Hypothesis of oxaliplatin-Induced 
Neurotoxicity
Although calcium regulation involves several organs and 
hormones, vitamin D is known to be an integral compo-
nent for numerous physiological functions of calcium at tis-
sue and cellular levels. In addition to its well-known effect 
on bone health, the neuromuscular system is now recognized 
as another important target for the wide-ranging effects of 
this hormone. A number of publications have addressed the 
role of vitamin D in diseases such as multiple sclerosis and 
Parkinson’s disease.54–56 Even more intriguing are laboratory 
data showing the neuroprotective effects of the hormone in 
laboratory models of Parkinson’s disease and amyotrophic 
lateral sclerosis.57–59 However, these data are tempered by the 
understanding that epidemiologic studies suggest correlation 
rather than causation; while success observed in preclinical 
models may not fully translate in human trials. Nonetheless, 
these data do suggest that the neuromuscular system may be 
another target of the pleiotropic effects of vitamin D. Hence, 
these data cannot be totally eschewed. What remains as the 
most relevant issue of this article is to elucidate a link between 
oxaliplatin and the microtubule and generate a hypothesis to 
drive a proof-of-concept clinical study.
Intuitively, any neuroprotective strategy aimed at pre-
serving microtubule function would be irrational if both 
antitumor and neurotoxic effects were invariably linked to 
microtubule dysfunction. As such, effective preventive thera-
pies for the traditional microtubule inhibitors discussed above 
would be extremely challenging. However, effective preven-
tion of neurotoxicity may be achievable if disruption of micro-
tubule function was independent of the dominant antitumor 
mechanism. Such may be the case with the platinum analogs.
Given this principle, and the vitamin’s link to calcium, 
the supposition that vitamin D may be clinically beneficial 
appears not only suspicious but also irrational. If so, then what 
would support the apparent discordance attached to the pro-
posed beneficial effect of vitamin D? The answer may reside 
in the relationship between vitamin D and the microtubule. 
As indicated previously, microtubules are relatively simple, yet 
paradoxically complex, intracellular polymers. Regardless of 
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manner, deregulation of the microtubule-organizing center 
or the microtubule itself results in mitotic arrest, the pur-
ported mechanism of tumor cell death. However, compelling 
evidence suggests that alteration of tubulin dynamics also 
increases the risk of toxicity to peripheral neurons, an adverse 
effect observed with all microtubule inhibitors. Even though 
the factors for the increased sensitivity of neuronal tissue to 
the antimicrotubule inhibitors remain elusive, a proffered 
explanation was provided earlier in this article. Briefly, the 
pathologic process could be described in the following manner. 
While synthesis of tubulin monomers is restricted to the per-
ikaryon, polymerization occurs distally in regions of axonal 
growth.26 Limitation of these two processes emphasizes 
an orderly mechanism for transporting tubulin and other 
microtubule-essential proteins required for constructing the 
neuronal cytoskeleton.27 Indeed, the ultimate shape of the 
cytoskeleton, integrity of the intracellular protein transport 
system, and function of the nervous system are dependent on 
the tubulin network.
Having established a biological link between the micro-
tubule and neurotoxicity leaves the larger, but not impos-
sible, task of elucidating a connection between oxaliplatin, 
the microtubule, and vitamin D. Even though not classified 
as antimicrotubule agents, platinum compounds have been 
shown to form platinum-tubulin adducts causing denatura-
tion of tubulin, disruption of polymerization, and inhibi-
tion of the microtubule.60 Of particular importance was the 
finding that disruption of microtubule function has been 
shown to result in a marked decrease in the formation of the 
active hormone, 1α,25(OH)2D3, not because of decreased 
cellular uptake of 25(OH)D3, but rather altered substrate 
transport. If so, then supraphysiological concentrations of 
25(OH)D3 may be able to correct the defect without alter-
ing oxaliplatin’s antitumor effect. In fact, vitamin D may 
have the opposite effect of increasing the antitumor effect 
of oxaliplatin.61
conclusion
Reasonably compelling evidence suggests an association that 
exists between cytoskeletal and axonal function, neurotoxicity, 
oxaliplatin, and vitamin D. And perhaps of equal impor-
tance is the possibility of correcting a ubiquitous irony in 
clinical research. In this context, a vitamin that may modu-
late numerous protective effects and costs only a few pennies a 
day can be considered a worthy clinical trial investment. Such 
a clinical study is currently being conducted to evaluate the 
validity of this hypothesis.
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